RxSIGHT

Investor Presentation

November 2026



Disclaimer & Forward-looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements and are generally identified by words such as “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” “forecast,” “budget,” and variations of such words or similar expressions. Statements regarding past performance, efforts or results from which inferences or assumptions about future performance may be drawn may also constitute forward-looking statements. Past performance or results are not necessarily indicative of future performance or results.

Forward-looking statements are based on the current beliefs of RxSight, Inc. (“RxSight,” “we” or “us”) management, as well as assumptions made by and information currently available to RxSight. Such statements reflect our current expectations regarding future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions.

These statements may include, without limitation, statements regarding: (i) our expectations for future financial and operating performance, including market trends, competitive dynamics and LAL adoption and utilization; (ii) our U.S. commercial transformation, including the expansion of our sales force, enhancements to customer engagement and practice support, and the anticipated timing and impact of these initiatives; (iii) our organizational restructuring, expected operating expense savings, improvements in operating efficiency and ability to strategically allocate resources toward our highest-priority initiatives; (iv) our next-generation adjustable lens pipeline, including anticipated product benefits and capabilities, development activities, potential patient populations, regulatory approvals and timelines; (v) the anticipated progress, benefits and opportunities associated with our strategic collaboration with Alcon, including potential milestone payments, royalties and the timing and amount of revenue recognition, as well as RxSight's and Alcon's respective rights and obligations under the collaboration agreement; and (vi) our long-term business strategy, potential growth opportunities, and financial outlook and plans to resume providing financial guidance for 2027 when we report our fourth-quarter 2026 results.

These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including, without limitation, risks relating to increased competition, market conditions, customer adoption and utilization of our products, our ability to successfully implement our commercial transformation and realize its anticipated benefits, the effectiveness and timing of our sales-force expansion and related initiatives, our ability to achieve anticipated cost savings and operating efficiencies from our organizational restructuring, and our ability to balance ongoing investments with financial discipline.

Additional risks include those relating to the RxSight-Alcon collaboration, including uncertainty as to whether its anticipated benefits and opportunities may be realized, may take longer to realize or may cost more than expected; unexpected hurdles, costs or delays; challenges associated with technology transfer, development and manufacturing; risks inherent in new product development, including obtaining regulatory approvals; intellectual property, operational, financial and other risks associated with collaborating with third parties; uncertainty regarding the commercial success of future products; and the ability of RxSight and Alcon to successfully execute their respective obligations and strategic plans.

Additional risks and uncertainties are described in our prior press releases and filings with the U.S. Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in our most recently filed Quarterly Report on Form 10-Q and in subsequent filings with the SEC, which are available at www.sec.gov. We caution you not to place undue reliance on any forward-looking statement, which speaks only as of the date hereof. We undertake no obligation to update any forward-looking statement or other information in this presentation, except as required by law.

This presentation contains estimates, projections and other information concerning our business, our industry and the markets for our products, including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained industry, market and similar data from internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. In some cases, we do not expressly identify the sources from which these data are derived. Information based on estimates, forecasts, projections, market research or similar methodologies is subject to risks and uncertainties, and actual events or circumstances may differ materially from those assumed in such information.



OUR VISION

Transform cataract surgery outcomes via the power of **adjustability**

Light Adjustable Lens (LAL) Delivers a Personalized Approach to Vision Correction

LAL Benefits:


- Targeted refractive accuracy
- Customization to patient lifestyle
- High patient satisfaction and confidence

Quality of Vision


Light Adjustable Lens™

Range of Vision












Postoperative Adjustability Delivers Unmatched Refractive Precision




Other Lenses

LAL eyes have

14.5 X

better odds of achieving optimal visual outcomes (absolute MRSE and MRCyl ≤ 0.50 D)[1]



LAL

1. Data on file - RxSight Post-Approval Study

Strong Clinical Outcomes and Physician Confidence Reinforce LAL's Value

Real world data from over 7,000 eyes

ACCURACY

>94%

+/- MRSE [1]

BINOCULAR OUTCOMES

>90%

20/25 distance and J2 near without glasses [1]


LAL Customer Survey

90%


believe LAL provides highest quality of vision [2]

79%

would select for their own premium IOL surgery (vs 11% for multifocal and 7% EDOF) [2]







1. RxSight Data on File: PMCS-002
2. 2025 RxSight Customer Survey

LAL Delivers Compelling Practice Economics

Expand the Premium Market

Data shows 40% of LAL patients would have otherwise chosen a standard, non-premium lens[1]

Command a Premium Price

Patients demonstrate a high willingness to pay for customized quality, supporting a significant price premium over fixed alternatives

Unify the Care Team

Enables both surgeons and optometrists to actively participate in and benefit from the premium IOL segment

$2,064[1]

Average additional practice net revenue per LAL implanted



1. Haffey & Company 2024 Economic Study of LAL Users

Key Strategic Priorities

Strengthening the U.S. LAL business while advancing the long-term potential of adjustability

1

U.S. Commercial Transformation

Drive deeper LAL adoption through stronger execution, customer engagement and practice integration

2

Next-Generation Innovation

Expand the patient population that can benefit from adjustability while improving workflow and performance

3

Alcon Collaboration

Advance development of adjustable presbyopia-correcting IOLs to extend the reach of adjustability

U.S. Commercial Transformation

Strengthening leadership, expanding field capabilities and improving operating efficiency to support deeper LAL adoption



Strengthened Commercial Leadership

Appointed experienced eye care leaders Taryn Conway and Frank Shields to lead commercial transformation



Expanded U.S. Sales Force

Nearly doubled the sales team to deepen customer engagement and practice support, with training and territory ramp-up underway



Building a Scalable Commercial Model

Leveraging insights from high-utilizing practices to strengthen physician education, patient selection and workflow integration

Drive deeper LAL adoption through more consistent execution across our existing customer base

Next Generation Innovation

Improved Workflow with Fewer Required Visits

Expanded Patient Choice

Leverages Adjustability Infrastructure



Next Generation LAL

Best-in-class visual quality and optical clarity with postoperative refractive optimization to consistently achieve targeted visual outcomes

LAL Toric

Built-in toric correction with postoperative refinement of residual sphere and cylinder to maximize visual acuity

Next Generation LAL +

Improved intermediate vision for everyday activities while preserving high-quality optical performance, with adjustability enabling precise refractive targeting

Alcon Collaboration Products

Alcon simultaneous vision intraocular lenses (“SVIOLs”) combined with RxSight's light-adjustable technology, enabling surgeons to fine-tune visual outcomes after surgery

Product candidates described above and related timelines are subject to regulatory approvals

Alcon Collaboration

RxSight and Alcon are collaborating to develop Simultaneous Vision Intraocular Lenses (“SVIOLs”), extending adjustability into presbyopia-correcting IOLs

RxSIGHT Alcon

Program Overview

Collaboration Product

Simultaneous Vision Intraocular Lenses

Strategic Objective

Combine RxSight’s light-adjustable technology with Alcon’s presbyopia-correcting IOL expertise

Collaboration Progress

Initial 120-day period complete; program progressing as planned

Economics


$60M	Upfront payment[1]
Up to $140M	Additional milestone payments[1]
30%	Royalties on net sales[1]

License: Non-exclusive license

Term: 10 years from first commercial sale; autorenewal for additional 5-year terms

1. All payments are subject to the terms and conditions of the Collaboration Agreement. A description of RxSight’s and Alcon’s respective rights and obligations under the Collaboration Agreement (including material terms and conditions) may be found in the Current Report on Form 8-K filed on July 6, 2026, with the Securities and Exchange Commission (SEC) and the full text of the Collaboration Agreement may be found in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 filed on August 5, 2026 with the SEC.

Third Quarter 2026 Results



$24.6M
Total Company Revenue[1]

23,128
LALs Sold

$255M
Cash, Cash Equivalents & ST Investments[2]

Light Adjustable Lens™

1. Including revenue recognized from Alcon collaboration agreement
2. Including $60 million received from Alcon

Building a Stronger Foundation for Long-Term Success

Differentiated Technology. Clear Priorities. Focused Execution.

Differentiated Platform

Strong clinical outcomes and physician confidence

Commercial Transformation

New leadership, expanded field capabilities and deeper customer engagement

Expanding the Reach of Adjustability

Next-generation innovation and the Alcon collaboration

Financial Strength & Discipline

Strong balance sheet and a more efficient operating model

RxSIGHT

Thank You

